Welcome to our dedicated page for Arrivent Biopharma news (Ticker: AVBP), a resource for investors and traders seeking the latest updates and insights on Arrivent Biopharma stock.
ArriVent BioPharma Inc (AVBP) is a clinical-stage biopharmaceutical leader developing targeted oncology treatments for unmet medical needs. This news hub provides investors and healthcare professionals with essential updates on the company's progress in advancing innovative cancer therapies.
Access timely reports on clinical trial developments, regulatory milestones, and strategic partnerships. Our curated collection includes updates on firmonertinib's clinical studies, FDA designations, licensing agreements, and pipeline expansion through next-generation antibody-drug conjugates.
Key content categories include clinical trial results, regulatory submissions, research collaborations, and scientific presentations. Bookmark this page for centralized access to verified updates about AVBP's work in precision oncology and NSCLC treatment advancements.
ArriVent BioPharma (Nasdaq: AVBP) reported its full year 2024 financial results and key milestones. The company achieved target enrollment of 375 patients in its global Phase 3 study of firmonertinib for first-line NSCLC with EGFR exon 20 insertion mutations. Clinical data showed robust responses for firmonertinib in first-line NSCLC EGFR PACC mutations.
Financial highlights include cash and equivalents of $266.5 million as of December 31, 2024, expected to fund operations into 2026. The company reported a net loss of $80.5 million for 2024, compared to $69.3 million in 2023. R&D expenses increased to $79.0 million from $64.9 million in 2023.
Pipeline developments include selecting ADC candidate ARR-002 for IND enabling studies, adding ARR-217 through Lepu Biopharma collaboration, and entering an ADC partnership with Alphamab. The company expects to provide updates on firmonertinib PACC development plans and Phase 3 top-line data timing in 2025.
ArriVent BioPharma (AVBP) has secured an exclusive global license agreement with Lepu Biopharma for MRG007, a novel antibody drug conjugate (ADC) targeting gastrointestinal cancers, for all territories outside Greater China. The deal includes a $47 million upfront and near-term milestone payment, with potential additional payments up to $1.16 billion based on development, regulatory, and sales milestones, plus tiered royalties.
MRG007 has demonstrated strong antitumor activity in preclinical models of GI cancers and favorable therapeutic index in IND enabling studies. The first Investigational New Drug (IND) submission is planned for the first half of 2025, initially focusing on colorectal, pancreatic, and other GI cancers. The company confirms that the agreement's financial terms, including upfront payment and R&D costs, maintain ArriVent's expected cash runway into 2026.
ArriVent BioPharma (Nasdaq: AVBP) reported Q3 2024 financial results with cash and cash equivalents of $282.9 million, expected to fund operations into 2026. The company reported increased R&D expenses of $58.9 million and G&A expenses of $11.8 million for the nine months ended September 30, 2024. Net loss widened to $59.9 million.
The company's lead drug firmonertinib showed positive results in treating NSCLC patients with EGFR PACC mutations, including those with brain metastases. Top-line data from the Phase 3 FURVENT trial for firmonertinib in NSCLC with EGFR exon 20 insertion mutations is expected in 2025.
ArriVent BioPharma (Nasdaq: AVBP) announced positive interim data from its Phase 1b FURTHER trial for firmonertinib in first-line EGFR PACC mutant non-small cell lung cancer (NSCLC) at the 2024 World Conference on Lung Cancer. Key highlights include:
- 81.8% overall response rate (ORR) and 63.6% confirmed ORR at 240mg dose by blinded independent central review (BICR)
- 46.2% confirmed ORR in CNS metastases
- 90.9% of patients with confirmed responses remained on study
- Generally well-tolerated safety profile
Firmonertinib showed promising dose-dependent activity across EGFR PACC mutations and demonstrated CNS antitumor activity. These results suggest potential as an effective oral, chemotherapy-free treatment for this underserved patient population.
ArriVent BioPharma (Nasdaq: AVBP) reported Q2 2024 financial results and highlighted recent progress. Key points include:
1. Upcoming presentation of clinical proof-of-concept data for firmonertinib in EGFR PACC mutant NSCLC at WCLC 2024.
2. New ADC collaboration agreement with Alphamab, expanding ArriVent's oncology pipeline.
3. Financial position: $298.7 million in cash and cash equivalents, expected to fund operations into 2026.
4. R&D expenses increased to $38.8 million for H1 2024, up from $30.6 million in H1 2023.
5. Net loss of $39.3 million for H1 2024, compared to $33.7 million in H1 2023.
6. Anticipating top-line Phase 3 data for firmonertinib in NSCLC with EGFR exon 20 insertion mutations in 2025.
ArriVent BioPharma (Nasdaq: AVBP) will present interim randomized Phase 1b FURTHER data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at the 2024 World Conference on Lung Cancer (WCLC). The presentation, selected for the Presidential Symposium, marks the first prospectively designed randomized clinical data for a small-molecule EGFR tyrosine kinase inhibitor in this specific patient population. The study, titled 'FURTHER: A Global, Randomized study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations,' will be presented on September 9, 2024. ArriVent will also host a virtual webinar on the firmonertinib program on the same day at 4:30pm ET.
ArriVent BioPharma has entered a collaboration with Jiangsu Alphamab Biopharmaceuticals to develop and commercialize novel antibody drug conjugates (ADCs) for cancer treatment. Under the agreement, ArriVent will utilize Alphamab's ADC research platform, while Alphamab will leverage ArriVent's global development expertise. The agreement includes potential milestone and upfront payments to Alphamab worth up to $615.5 million, excluding Greater China where Alphamab retains development and commercialization rights. Alphamab will also receive tiered sales royalties from ArriVent for each ADC product.
ArriVent BioPharma has appointed Dr. John Hohneker to its Board of Directors.
Dr. Hohneker brings over 30 years of biopharmaceutical leadership and drug development experience, previously holding key roles at Anokion SA, Forma Therapeutics, and Novartis AG.
He currently serves on the Boards of Carisma Therapeutics, Curis, Sonata Therapeutics, and Trishula Therapeutics.
Dr. Hohneker's expertise is expected to aid in advancing ArriVent's pipeline, including its lead candidate firmonertinib, aimed at addressing unmet cancer patient needs.
ArriVent BioPharma reported strong financial results for the first quarter of 2024, with a cash position of $317.4 million, showcasing positive progress in advancing their clinical programs. The company presented preclinical data on firmonertinib at the AACR Annual Meeting, demonstrating its effectiveness across a wide range of mutations in NSCLC. They also dosed the first patient in a Phase 1b combination study with ICP-189 for NSCLC patients with EGFR classical mutations. The company is on track to deliver proof-of-concept data in 2024 and is making strides in selecting a next-generation ADC development candidate.
